Last reviewed · How we verify
NCT06833723
Development of a Multi-omics Prediction Model for Immunotherapy Response in Triple-Negative Breast Cancer Subtypes
trial testing Retrospective Data Collection and Analysis in Breast Neoplasms in 1,000 participants. Participants enrolled and being followed up; not accepting new ones.
17 December 2025
Quick facts
| Lead sponsor | Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 17 April 2025 |
| Primary completion | 17 December 2025 |
| Estimated completion | 17 November 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Retrospective Data Collection and Analysis
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
Sponsor
Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
Who can join
18 and older, female only, with Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to collect clinical samples from breast cancer patients who have undergone or are expected to undergo immunotherapy at our institution. The samples, including fresh tissue from diagnostic punctures, residual tumor tissue post-surgery, blood samples, and imaging data, will be used to build a predictive model for immunotherapy efficacy. The research will employ proteomics, transcriptomics, metabolomics sequencing, imaging mass cytometry (IMC), and spatial transcriptomics to construct a multi-omics, multi-dimensional (temporal and spatial) model to predict the effectiveness of immunotherapy.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Mapping the rapid growth of multi-omics in tumor immunotherapy: Bibliometric evidence of technology convergence and paradigm shifts.
Dong H, Wang X, Zheng Y, Li J, et al · · 2025 · cited 5× · PMID 40275437 · DOI 10.1080/21645515.2025.2493539
Verify or expand the search:
- PubMed search for NCT06833723
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Retrospective Data Collection and Analysis
Trials testing the same drug.
- NCT07167095 — 90-Day Mortality After Emergency Department Discharge in Advanced Cancer · completed
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06833723 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences
- Last refreshed: 15 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06833723.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing